IPO de Coimbra; Servico de Oncologia Medica
Coimbra, Portugal
Cancer treatment center in Coimbra
Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra
About IPO de Coimbra; Servico de Oncologia Medica
"O IPO de Coimbra, tem a missão de desenvolver ações nos domínios da prestação de cuidados de saúde"
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
10
Pfizer
2
Bayer
1
BioNTech SE
1
EMD Serono Research & Development Institute, Inc.
1
Eisai Inc.
1
Escola Superior de Enfermagem de Coimbra
1
Genmab
1
Grupo de Investigacao do Cancro Digestivo
1
Ipsen
1
Janssen Research & Development, LLC
1
Clinical Trials at IPO de Coimbra; Servico de Oncologia Medica
During the past decade, IPO de Coimbra; Servico de Oncologia Medica conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 6 clinical trials were completed, i.e. on
average, 35.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
2005-07-01
2008-07-01
Unknown status
45
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
2009-04-16
2013-04-12
Terminated
1,100
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
2009-06-29
2015-09-09
Completed
921
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
2012-06-01
2019-09-20
Completed
1,436
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
2012-09-24
2018-07-13
Completed
498
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
2012-08-01
2015-06-01
Completed
163
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
2013-08-19
2017-05-05
Completed
296
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "IPO de Coimbra; Servico de Oncologia Medica" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Pfizer" with 2 trials
sponsored, "Bayer" with 1 trials sponsored, "BioNTech SE" with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc."
with 1 trials sponsored. Other sponsors include 5 different institutions and
companies that sponsored additional 15 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "IPO de Coimbra; Servico de Oncologia Medica"
#1 collaborator was "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator, "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator, "Helsinn Healthcare SA" with 1 trials as a collaborator and "Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 6 trials.
Clinical Trials Conditions at IPO de Coimbra; Servico de Oncologia Medica
According to Clinical.Site data, the most researched conditions in "IPO de Coimbra; Servico de Oncologia Medica" are
"Breast Cancer" (3 trials), "Glioblastoma" (2 trials), "Squamous Cell Carcinoma of the Head and Neck" (2 trials), "Advanced Cholangiocarcinoma" (1 trials) and "Breast Neoplasms" (1 trials). Many other conditions were trialed in "IPO de Coimbra; Servico de Oncologia Medica" in a lesser frequency.
Clinical Trials Intervention Types at IPO de Coimbra; Servico de Oncologia Medica
Most popular intervention types in "IPO de Coimbra; Servico de Oncologia Medica" are "Drug" (20 trials), "Radiation" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (6 trials), "Atezolizumab" (3 trials), "Avelumab" (2 trials), "Bevacizumab" (2 trials) and "Cisplatin" (2 trials). Other intervention names were less common.
Clinical Trials Genders at IPO de Coimbra; Servico de Oncologia Medica
The vast majority of trials in "IPO de Coimbra; Servico de Oncologia Medica" are
23 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at IPO de Coimbra; Servico de Oncologia Medica
Currently, there are NaN active trials in "IPO de Coimbra; Servico de Oncologia Medica".
undefined are not yet recruiting,
2 are recruiting,
10 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 8 completed trials in IPO de Coimbra; Servico de Oncologia Medica,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in IPO de Coimbra; Servico de Oncologia Medica, 0 "Phase 1"
clinical trials were conducted, 6 "Phase 2" clinical
trials and 16 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".